摘要
目的:探讨维吾尔族、汉族糖尿病合并冠心病患者、冠心病患者、糖尿病患者血脂、血糖、体重指数等常见危险因素的分布情况,同时探讨载脂蛋白A5(APOA5)、载脂蛋白B(APOB)、胆固醇脂转运蛋白(CETP)基因多态性在前述各组中的分布特点及在汉族、维吾尔族之间的差异,并进一步明确APOA5、APOB、CETP基因多态性对汉族、维吾尔族冠心病、糖尿病、冠心病合并糖尿病患者的血脂代谢影响以及与上述疾病的关系。方法:选取2008年1月至2008年9月在心脏中心及内分泌科、干部综合内科住院的患者作为研究对象,冠心病患者266例,男性196例,女性70例;其中合并糖尿病154例,男性110例,女性44例;单纯糖尿病患者122例,其中男性84例,女性38例。对照组137例,其中男性77例,女性60例。测量身高、体重、血糖、血总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、载脂蛋白A(APOA)、载脂蛋白B(APOB)、LPa等指标,计算载脂蛋白B/A比值,记录糖尿病病程、吸烟、年龄等,计算吸烟指数,进行不同组间比较,应用非条件Logistic回归分析糖尿病合并冠心病、冠心病、糖尿病发病的危险因素。同时提取白细胞基因组DNA,用聚合酶链反应(PCR)扩增和连接酶法检测CETP、APOA5、APOB基因多态性,分析汉族、维吾尔族基因型频率、等位基因频率的差别以及以上多态性与糖尿病合并冠心病的发病关系。结果:1)APOA5基因1131T/C分型提示:冠心病合并糖尿病组等位基因C携带者(CC+TC)TG水平及LP(a)明显高于C非携带者(TT);冠心病组(CHD)及冠心病合并糖尿病组(CHD+DM)的等位基因频率明显高于对照组,糖尿病组和对照组间C等位基因频率无统计学差异。病例组与对照组维吾尔族、汉族基因型频率之间无差别,但冠心病和糖尿病组维吾尔族C等位基因频率高于汉族。2) APOB基因EocRI多态性与血脂指标没有明显关联性,其中A等位基因频率虽然在冠心病组、糖尿病组高于对照组,但未达到统计学差异,在糖尿病合并冠心病组与对照组相同,A等位基因频率与冠心病发病率不存在一致性,冠心病组A等位基因频率最高,其次为糖尿病组、糖尿病合并冠心病组、对照组;病例组和对照组间A等位基因频率分布无显著性差异。冠心病合并糖尿病组A等位基因携带者BMI高于G等位基因携带者;冠心病组及冠心病合并糖尿病组维吾尔族GA基因型频率和等位基因频率高于汉族,而在糖尿病组中无差异;3) CETP基因D442G在四组人群中均未发现突变纯合子GG基因型,冠心病组CETP基因D442G突变频率为4.5%(5/112),冠心病合并糖尿病组突变率3.9%(6/154),糖尿病组突变率4.9%(6/122),而对照组突变频率为3.7%(5/136),病例组与对照组突变频率均无统计学意义(P>0.05)。两组人群均符合Hardy-Weinberg平衡,具有群体代表性。维吾尔族和汉族G等位基因频率无统计学差异,DD和DG基因型在冠心病、冠心病合并糖尿病组的血脂水平比较无统计学差异;4)糖尿病组、冠心病组、糖尿病合并冠心病组TG、TC、LDL、APOB、血糖均高于对照组,达到统计学差异,P值<0.05,三组之间年龄、BMI、HDL-C、LDL-C、APOA1、吸烟指数均有差别,其中糖尿病合并冠心病组更高于糖尿病组和冠心病组,但后两组间没有明显差别。冠心病组中维吾尔族HDL-C明显低于汉族,在糖尿病组中各项指标无明显差异。糖尿病合并冠心病组维吾尔族年龄均值低于汉族,BMI高于汉族。对照组内维吾尔族BMI、FBG、TG、APOB/A高于汉族。⑤年龄、BMI、TG、LDL-C、LP-a是冠心病的独立危险因素,女性是保护因素,其中LDL-C是最突出的危险因素。年龄、BMI、TC、LDL-C、LP-a是冠心病合并糖尿病的独立危险因素,女性、HDL-C是保护因素。年龄、TC、TG是糖尿病的独立危险因素。结论:APOA51131C等位基因可能与TG、LP-a升高有关,C等位基因可能是维吾尔族糖尿病合并冠心病的易感基因;APOB基因EocRI基因的A等位基因与血脂水平没有明显关系,A等位基因可能增加了维吾尔族糖尿病合并冠心病及冠心病的易感性;A等位基因可能是维吾尔族冠心病及冠心病合并糖尿病的易感基因;A等位基因与糖尿病合并冠心病腹型肥胖相关,与脂代谢相关。CETP基因D442G中GG纯合子突变极少见,G等位基因与血脂和糖尿病合并冠心病及冠心病、糖尿病的可能没有关系,维吾尔族该基因位点突变频率与汉族之间没有差异。高血脂、高血压、高血糖、体重指数升高是糖尿病合并冠心病的危险因素及冠心病的危险因素,高血压、高血脂、体重指数增加是糖尿病的危险因素。在健康人群中维吾尔族较汉族有更明显的脂代谢紊乱,糖尿病合并冠心病中,维吾尔族发病年龄较年轻。
Objective:To investigate the Han,Uygur diabetes patients with coronary heart disease,coronary heart disease patients,diabetic patients with blood lipids,blood sugar, blood pressure and other common risk factors for the distribution,at the same time explore the APOA5,APOB,CETP gene polymorphisms with coronary heart disease in diabetes,and coronary heart disease,and diabetic patients distribution characteristics, clear whether there are differences,respectively,to explore and further define APOAS, APOB,CETP gene polymorphisms with the Han,Uygur coronary heart disease,diabetes, coronary heart disease associated with diabetes mellitus.Methods:from January 2008 to October 2008 in the heart center and inpatient endocrine patients as research subjects,266 cases of patients with coronary artery disease,196 cases of male,female 70 cases;one of 154 cases with diabetes,110 cases of male,female 44 cases;122 cases of patients with diabetes alone,one of 84 cases of male,female 38 cases.137 cases of the control group, one of 77 cases of male,female 60 cases.Measurement of height,weight,blood glucose, blood lipids,systolic blood pressure,diastolic blood pressure,blood total cholesterol, triglyceride,high density lipoprotein,low density lipoprotein and other indicators, Calculation of apolipoprotein B/A ratio and Smoking index calculation for different groups to compare,contrast,application of non-conditional Logistic regression analysis of diabetic patients with coronary heart disease,coronary heart disease,diabetes risk factors.At the same time,extracting leukocyte genomic DNA,respectively,by polymerase chain reaction(PCR) amplification and conection enzym method detection of CETP,APOA5,APOB gene polymorphism analysis of the above polymorphisms with coronary heart disease and diabetes incidence relations.Results:1) APOA5 gene 1131T/C sub-type Tip:coronary heart disease with diabetes mellitus group C allele carriers(CC+TC) TG and LP(a) levels were significantly higher than the C non-carriers (TT);CHD group and CHD with diabetes allele frequencies significantly higher in the control group.Diabetes group and the control group C was no significant difference in allele frequencies.Case Uighur groups,no difference between genotype frequencies of the Han,in coronary heart disease with diabetes mellitus group Uygur C allele frequency is higher than the Han in CHD group and diabetes group.2) APOB gene polymorphism and blood lipid target EocRI no obvious relevance,although one of A allele frequencies in theCHDgroup,diabetic control group,but did not reach statistical significance,patients with coronary heart disease in diabetic and control groups the same,A allele frequency and incidence of coronary heart disease there is no consistency,coronary heart disease allele frequency of group A the highest,followed by diabetic group,diabetic patients with coronary heart disease group and the control group;A allele with elevated blood lipids and crown heart disease unrelated to happen,cases and controls the distribution between the A allele frequency was no significant difference.Group A allele carriers of coronary heart disease with diabetes is higher than G allele carriers BMI;in coronary heart disease group and CHD with diabetes group Uygur GA genotype frequency and allele frequency is higher than the Han nationality,and in the group of diabetic there is no difference.3) D442G in the CETP gene among the four groups were found mutation D442G homozygote GG genotype,coronary heart disease group D442G mutation in CETP gene frequency of 4.5%(5/112),coronary heart disease with diabetes mutation rate of 3.9% (6/154),diabetes,mutation rate 4.9%(6/122),while the control group,3.7%mutation frequency(5/136),case and control groups were not statistically significant mutation frequency(P>0.05).Two groups are consistent with Hardy- Weinberg balance,with a representative group.Conclusion:The high blood lipids,hypertension,high blood sugar, body mass index is higher in diabetic patients with coronary heart disease risk factors of coronary heart disease group similar group of diabetic hypertension,high blood lipids, body mass index increase in risk factors.4) diabetic group,coronary heart disease group, diabetic patients with coronary heart disease group TG,TC,LDL,APOB,blood sugar were higher,reaching statistical difference,P value<0.05,Between the three age groups, BMI,HDL-C,LDL-C,APOA1,showed differences in smoking,one group of diabetic patients with coronary heart disease higher in the diabetic group and coronary heart disease group,but after no significant differences between the two groups.Coronary heart disease Uighur group HDL-C was significantly lower than the Han,in the diabetic group, no significant differences in the target.,Diabetic patients with coronary heart disease is lower than the mean age group of Uygur Han,BMI is higher than the Han.Uygurs in the control group BMI,,FBG,TG,APOB/A is higher than the Han.5) age,BMI,TG,LDL-C, LP-a is an independent risk factor for coronary heart disease,women are protective factors,LDL-C is one of the most prominent risk factors.Age,BMI,TC,LDL-C,LP-a coronary heart disease and diabetes are independent risk factors,women,HDL-C are protective factors.Age,TC,TG are an independent risk factor for diabetes.Conclusion: APOA5 allele C may be associated with increased TG and LP-a related,C allele are probably Uygur diabetes susceptibility gene with coronary heart disease;APOB gene A allele EocRI gene target with no obvious relationship between blood lipid,Uygur A allele and diabetic patients with coronary heart disease and coronary heart disease may be related;A alleles are possible coronary heart disease and diabetic with coronary heart disease susceptibility gene Uygur;CETP gene D442G in G and serum lipids and diabetes mellitus with coronary heart disease and coronary heart disease,diabetes probably does not matter.High blood cholesterol,high blood pressure,high blood sugar,body mass index increase in diabetes mellitus are risk factors for coronary heart disease and risk factors for coronary heart disease,hypertension,hyperlipidemia,increased body mass index are risk factors for diabetes.Uygur Han has more obvious than the lipid metabolism disorders,diabetes mellitus with coronary heart disease in younger age at onset Uygur.
引文
[1]Bradley E1Aouizerat,Medha Kulkami,David Heilbron,et al.Genetic analysis of a polymorphism in the human apoA-V gene:effect on plasma lipids[J].J Lipid Res,2003,44:1167-71.
[2]Nabila AA,Olusegun AM,Abayomi OA,et al.Serum lipoprotein(a)concentration as a cardiovascular risk factor in Kuwaiti type diabetic patients[J].J Diabetes Complications,2001,15:270.
[3]Kesavulu MM,Kameswara BR,Giri R,et al.Lipid peroxidation-and antioxidant enzyme status in type 2 diabetics with coronary heart disease[J].Diabetes Res Clin Pract,2001,53:33.
[4]Mojiminiyi OA,Abdella N,Moussa MA,et al.Association of creactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2002,58:37.
[5]Matsumoto K,Sera Y,Abe Y,et al.Inflammation and insulin resistance are independently related to all cause of death and cardio-vascular events in Japanese patients with type 2 diabetes mellitus[J].Atherosclerosis,2003,169(2):317-324.
[6]Fuster,VGortoAM,Libby,Pet al.Pathogenesis of coronary disease:The biologicle of risk factors.JAmCollCardiol,1996,27:964-976.
[7]胡大-,马长生.心脏病学实践2004-规范化治疗.人民卫生出版社,2004:419.
[8]Frishman WH,Retter A,Mobati D,et al.Innovative drug targetsfor treating cardiovascular disease:adhesion molecules,cytokines,neuropeptide Y,calcinium,bradykinin,urotensin,and heat shockprotein.Cardiovascular Pharmacotherapeutics.2nd ed.New York:McGrawHill,2003:705-739.
[9]FalconeC,NespoliL,GeroldiD,eta,1 Silentmyocardial ischemia in diabetic and nondiabetic patientswith coronary artery disease.Int J Cardio,12003,90(2-3):219-227.
[10]张惠芬,迟家敏,王瑞萍.实用糖尿病学.人民卫生出版社,2001:420-421.
[11]Association found between the promoter region polymorphism in the apolipoproteinAV gene and the serum triglyceride level in Japanese school children[J].Hum Genet,2002;111:570-572.
[12]FubrergCD,HennekensCH,HulleySB,et al.Clinical epidemiology:The comptual basis of interpreting risk factors.JAmCollCardiol,1996:27:976-978.
[13]Cadiovascular disease risk factor:a new reason research.Report of a WHO Scientific Gropu.WHO Technical Report Series 841.Geneva:World Health Organization,1994.
[14]WoodD.Estbalished and emerging cardiovascular risk factors.AmHeartJ,2001,141:549-557.
[15]Executives coronary of the third report of the national cholesterol education Program CETP)Expert panelondetection,evaluation,and treatmen to high blood cholesterl in adults.JAMA,2001,285:2486-2497.
[16]Talmud PJ,Hawe E,Martin S,et al.Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides[J].Hum Mol Genet,2002;24(11):3039-3046.
[17]LusisAJ.Atheroselerosis.Nature,2000,407:233-241.
[18]Wang CH,Zhou X.Meta-analysis for relationship between apoE gene polymorphismand coronary heart disease.Zhonghua Yu Fang Yi Xue Za Zhi.2003 Sep;37(5):368-70.
[19]Rubin EM,Tall A.Perspectives for vascular genomics.Nature 2000,407:265-269
[20]Lusis AJ.Atherosclerosis.Nature 2000:407:233-41.
[21]Plump AS,Smith JD.Hayek T,et al.Severe hypercholesterolemia and atherosclerosis in apoliprotein E-deficient mice created by homologous recombination in ES cells.Cell 1992,71(2):343-53
[22]Walldius G,Jungner I,Holme I,et al.High apolipoprotein A-I,and improvement in the prediction of fatal myocardial(AMORIS study):a prospective study.Lancet 2001,358(9298):2026-33
[23]Pennacchio LA,Olivier M,Hubacek JA,et al.An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing[J]Science,2001;294(5540):169-73.
[24]Vander Vliet HN,Sammels MG,Leegwater AC,et allApolipoproteinAV:a novel apolipoprotein associated with an early phase of liver regeneration[J]J Biol Chem,2001;276(48):44512-20.
[25]Seda O Sedoval New apolipoprotein AV:comparative genomics meets metabolism[J].Physiol Res,2003,52:141-146.
[26]MaeraisC,VergesB,Chartieers et al.Apoa5Q139X truncation predisposes to late onset hyperchylomicronemia due to lipoprotein lipase impairment[J].Clin Invest.2005 Oct;115,(10),2862-9.
[27]Yan SK,Cheng XQ,Song YH,et al.Apolipoprotein A5 gene polymorphism 1131T>C:association with plasma lipids and type 2 diabetesmellitus with coronary heart disease in Chinese[J].Clin Chem.2005;43(6):607-12.
[28]HollanderW.Unified concept on the role of acid mucopolysaccharides and connective tissue proteins in the accumulation of lipids,lipoproteins,and calcium in the atherosclerotic plaque.Exp Mol Pathol.1996,25(1):106-120.
[29]Genest IJ,Huang LS,Herbert Mcnamara JR,et al.DNA Polymorphisms of the apolipoproteinB gene in patient with premature coronary artery diseases,Atherosclerosis,1990,82:7-17.
[30]Kauma H,Savolainen MJ,Heikldla R,et al.Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors.Hum Genet,1996,97:156-162.
[31]CorbexM,Poirier O,Fumeron F,et al.Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environmental interaction.Genet Epidemiol,2000,19:64-80.
[32]Ngoc-Dac,Philippe Gervois,Heidi Jakel.Apolipoprotein A5,a CrucialDeterminant of Plasma Triglycoride Levels,Is Highly Responsive to peroxism Proliferator activated Receptora Activators[J].J Biol Chem,2003;278(20):17982-5.
[33]Mehrabian M,Wen PZ,Fisler J,Davis RC,Lusis AJ.Genetic loci controlling body fat,lipoprotein metabolism,and insulin levels in a multifactorial mouse model.J Clin Invest.1998,101:2485-2496.
[34]Fruchart JC,Nierman MC,Stroes ESG,Kastelein JJP,Duriez P.New risk factors for atherosclerosis and patient risk assessment.Circulation.2004;109:(Suppl.Ⅲ)Ⅲ-15-Ⅲ-19.
[35]Szapary PO,Rader D.The triglyceride-high-density lipoprotein axis:an important target of therapy?Am Heart J.2004;148:211-221.
[36]Zilversmit DB.Atherogenesis:a postprandial phenomenon.Circulation.1979;60:473-485.
[37]Karpe F.Postprandial lipoprotein metabolism and atherosclerosis.J Intern Med.1999;246:341-355.
[38]Krauss RM,Siri PW.Dyslipidemia in type 2 diabetes.Med Clin North Am.2004;88:897-909.
[39]Krauss RM,Siri PW.Metabolic abnormalities:triglyceride and low-density lipoprotein.Endocrinol Metab Clin North Am.2004;33:405-415.
[40]Grundy SM.Small LDL,atherogenic dyslipidemia,and the metabolic syndrome.Circulation.1997;95:1-4.
[41]Krauss RM.Insulin resistance syndrome and dyslipidemia.Endocr Pract.2003;9(Suppl 2):67-72.
[42]Pennacchio LA,Rubin EM.Apolipoprotein A5,a newly identified gene that affects plasma triglyceride levels in humans and mice.Arterioscler Thromb Vase Biol.2003;23:529-534.
[43]Endo K,Yanagi H,Araki J,Hirano C,Yamakawa-Kobayashi K,Tomura S.Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren.Hum Genet.2002;111(1):570-572.
[44]Nabika T,Nasreen S,Kobayashi S,Masuda J.The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese.Atherosclerosis.2002;165:201-204.
[45]Pennacchio LA,Olivier M,Hubacek JA,Krauss RM,Rubin EM,Cohen JC.Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.Hum Mol Genet.2002;11:3031-3038.
[46]Ribalta J,Figuera L,Fernandez-Ballart J,Vilella E,Castro Cabezas M,Masana L,Joven J.Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia.Clin Chem.2002;48:1597-1600.
[47]Hanke H,Hanke S,Bruck B,et al.Inhibition of the protective effec of estrogen by progesterone in experimental atherosclerosis Atherosclerosis,1996,121(1):129-138.
[48]Maxime N,Audrey HC,Heidelinde J,et al.Insulin-Mediated DownRegulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway Role of Upstream Stimulatory Factor.Molecular and cel bio,2005,25(4):1 537-1 548.
[49]BIN,Yan SK,Li GP,et al.A single nucleotide polmorphism-1131T>C in the Apolipoprotein A5 gene is associated with an increased risk of coronary artery disease And alters triglyceride metabolism in Chinese.Mol Genet Metab.2004,83(3):280-286.
[50].Merkel M,Loeffler B,Kluger M,et al.Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.[J].Biol Chem.2005,3;280(22):21553-60.
[51].SchaaP FG,Rensen PC,Voshol PJ,et al.APOAV reduces plasma triglycerides by Inhibiting very low density lipoprotein-triglyceride(VLDL-TG)production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.[J]BiolChem.2004,279(27):27941-7.
[52].Fruchart-Najib jamila,Bauge Eric,Niculescu U,et al.Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.[J].Biochem Biophys Res Common.2004,319:397-404.
[53]Ribalta J,Figuera L,Fernandez Ballart J,et al.Newly identified apolipoprotein AV Gene predisposes to hihg Plasma triglycerides in familial combined hyperlipidemia.Clin Cheln.2002,48(9):1597-1600.
[54]Vu-Dac,-N;Gverois,-P;Jkael,-H,et al.Apolipoprotein AS,a crucial determinant of plasma triglyecride levels,is hihgly responsive to peroxisome prolierfators activated receptor alpha activators[J].J-Biol Chme.2oo3 May 16:275(20):17952- 17955.
[55]Vander Vliet HN,Sehapa FG,Levels JH,ottenhoff R,et al.Adneoviral Over expression of apolipoproteionA-V reduce serum lveles of rtiglycerides and Cholesteral in mice[J].Biochme BioPhys Res,2002,295:1156-1159.
[56]PriuerX,HubyT,CosteH,et al.Thyroid hormone regulates the hypotriglyceride mic gene ApOA5[J].J Bio Chme.2005 Jul 29;280(30):27533-27543.
[57]Tah-nudPJ,PalmenJ,Putt W,et al.Determination of the ufnctionality of commin Polymorphisms.J Biol Chem.2005,280(31):28215-28220.
[58]Kannel WB,Gordon T,Castelli WP.Role of lipids and lipoprotein fractions in assessing atherogenesis.The Framingham Study.Prog Lipid Res.1981,20:339-348.
[59]Aouizerat B,Kularni K,Heilbron D,et al.The effect of variation within the human apolipoprotein A-V gene on plasma lipids.Journal of lipid research,2003,44:1167-1173.
[60]Endo K,Yamgi H,Arak J et al Association found between the promoter region polymorphism in the apolipoprotein AV gene and the serum triglycerid level in Japanese School children.Hum Genet,2002,111:570-572.
[61]Lee KW,Ayyobi A,Frohlihc JJ,et al.APOA5 gene polymorphism modulates levels of triglyceride,HDL cholesterol and FERHDL but is not a risk factor for coronary disease.Atherosclerosis.2004,176(1):165-172.
[62]IshihaarM,KujiraokaT,IwaskaiT,et al.AsandwielmezTnye-likned immun osohbent assay for human Plasm apolipoproteinA-Vconcenrtation[J].J Lipid Res.2005,Sep;46(9):2015-2022.
[63]李向平,赵水平,聂赛等.载脂蛋白A5-1131T>C基因多态性对血脂的影响.医 学临床研究.2004.21(11):1245-1249.
[64]毕楠,郡盛恺,李国平等.冠心病患者载脂蛋白A5和载脂蛋白C3基因多态性的研究.华心血管病杂志2005,33(2):116-121.
[65]Hubacek JA,Horinek A,Skodova Z,et al.Hpertriglyceridemia:interaction between APOE and APOAV variants.Clin Chem.2005,51(7):1311 - 1313.
[66]Nabika T,Nasreen S,Kobayashi S,et al.The genetic effect of the apoprotein AV gene on the seruln triglyceride level in Japanese.Atherosclerosis.2002,165(2)201-204.
[67]Kim HK,Chang SA,Choi EK,et al.Association between plasma lipids,and apolipoproteins and coronary artery disease:a cross-sectional study in a low-risk Korean population.Int J Cardiol.2005;101:435-440.
[68]Marz W,Scharnagl H,Winkler K,et al.Low-density lipoprotein triglycerides associated with low-grade systemic inflammation,adhesion molecules,and angiographic coronary artery disease:the Ludwigshafen Risk and Cardiovascular Health study.Circulation.2004;110:3068-3074.
[69]Achari,V;Thakur,AK.Association of major modifiable risk factors among patients with coronary artery disease-a retrospective analysis.J Assoc Physicians India.2004;52:103-108.
[70]Walldius,G;Jungner,I;Hollne,I;Aastveit,AH;Kolar,W;Steiner,E.High apolipoprotein B,low apolipoprotein A-I,and improvement in the prediction of fatal myocardial infarction(AMORIS study):a prospective study.Lancet.2001;358:2026-2033.doi:10.1016/S0140-6736(01)07098o2.
[71]Boerwinkle E,Chan L.three codon insertion/deletion Polymorphyism in the signal Peptide region of the human aoplipoprotein B gene directly typed by the polymerase Chain reaction.Nucleic Acids Res,1989,17:4003.
[72]Visvikis S,Chan L,Siest G,et al.An insertion deletion Polymorphysim in the signal peptide of the human apolipoprotein B gene.Hum Genet,1990,84:373-375.
[73]Kazum i T,Kawaguchi A,H irano T,et al.Serum adiponectin is associated with high density lipoprotein cholesterol,triglycerides,and low density lipoprotein particle size in young healthy men[J].Metabolism,2004,53:589-593.
[74]Rosenson,R.Lipoprotein classification;metabolism;and role in atherosclerosis.In:Rose B.,editor.UpToDate.Wellesley,MA,USA:UpToDate;2005.
[75]Cavalli SA,Hirata MH,Salazar LA,et al.Apolipoprotein B gene polymorphisms:prevalence and impact on serum lipid concentrations in hypercholesterolemic individuals from Brazil.Clin Chim Acta,2000,302(1-2):189.
[76]肖志杰,谭利民,张贺,等.载脂蛋白E基因多态性与老年人脑出血和脑梗死关系的研究J.中华老年医学杂志,2005,24f2):112-1141.
[77]单江,施育平,傅国胜.血管紧张素转换酶基因多态性与冠心病危险因素的关系J.中华流行病学杂志,2000,21(3):208-2111
[78]贾崇奇,宁艳,刘同涛,等.内皮型-氧化碳合酶基因G894T变异与早发冠心病的关系J.中华流行病学杂志,2005,26(1):51-531
[79]Nishiwaki,Masato,Ikewaki,et al.Human lecithin:cholesterol acyltransferase deficiency:in vivo kinetics oflow density lipoprotein and lipoprotein-XJ.Arterioscle rosis,Thrombosis & Vascular Biology,2006,26(6):1370-13751
[80]Chan L.Apolipoprotein B,the major protein component of triglyceride-rich and low Density lipoproteins.J Biol Chem,1992,267:25621-25630.
[81]Young SG.Recent progress in understanding apolipoprotein B.Circulation,1990,82:1574-1594.
[82]Genest JJ,Ordovas JM,McNamara JR,et al.DNA Polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease.Atherosclerosis,1990,82:7-17.
[83]Hegele RA,Huang LS,Herbert PN,et al.Apolipoprotein B gene DNA Polymorphisms Associated with myocardial infarction.N Engl J Med,1986,315:1509-1515.
[84]Friedl W,Ludwig EH,Paulweber B,et al.Hypervariability in a minisatellite 3'of the Apolipoprotein B gene in patients with coronary heart disease compared with nomral contorl.J Lipid Res,1990,31:659-665.
[85]Boerwinkle E,Lee ss,Butler R,et al.Rapid typing of apolipoprotein B DNA Polymorphisms by DNA amplification:association between Ag epitopes of human apolipoproteinB-100,a single Peptide insertion/deletion Polymorphism,and a 3'flakning DNA.variable number of tandem repeats Polymorphism of the apolipoortein B gene.Atherosclerosis,1990;81:225-232.
[86]Blackhart BD,Ludwig EM,Pierotti VR,et al.Structure of human apolipoprotein B gene.J Biol Chem,1986,261:15364-15367.
[87]Huang LS,De Graaf J,Breslow JL.ApoB gene Msp I RFLP in exon 26 changes amino acid 3611 from Arg to Gln.J Lipid Res,1988,29:63-67.
[88]Knott TJ,Wallis SC,Pease RJ,et al.A hypervarriabte region3'to the human Apolipoprotein B gene.Nucleic Acids Res.1986,14:9215-9216.
[89]Huang LS,Breslow JL.Aunique A-T rich hypervariable minisatellite 3'to the apoB gene defines a high information restriction fragment length Polymorphism.J Biol Chem,1987,212:8952-8955.
[90]Hixson JE,Power PK,McMahan CA,et al.The human apolipoprotein B 3' Hypervariable region:detection of eight new alleles and comparison of allele Frequencies in blacks and whites.Hum Genet,1993,91:475-479.
[91]LusisAJ.Atherosclerosis.Nature,2000,407:233-241.
[92]Rantala M,Rantala T,Savolainen MJ,et al.ApolipoproteinB gene polymorphisms And serum lipids:meta-analysis of the role of genetic variation in responsiveness to diet.Am J Clin Nutr,2000,71:713-24.
[93]Tyberg-Hansen A,Nordestgaard BG,Gerdes CN,et al.Variation of apolipoprotein B gene is associated with myocardial infarction and lipoprotein levels in Danes.Atheroclerosis,1991.89:69.
[94]Hegele RA,Hunag LS,Herbert PN,et al.Apolipoprotein B gene DNA Polymorphisms associated with myocardial infarction.N Engl J Med,1986,315:1509-1515.
[95]Friedl W,Ludwig EH,Paulweber B,et al.Hypevrariability in aminisatellite3'of the apolipoprotein B gene in patients with coronary heart disease compaerd with nomral control.J Lipid Res,1990,31:659-665.
[96]Paulweber B,Friedl W,Krempler,et al.Association DNA polymorphisms at the apolipoprotein B gene locus with coronary heart disease and serum very low densitith lipoprotein levels[J].Atherosclersis,1990,10:17.
[97]Tybiaerg-Hansen A,wordestgaard BG,et al.Variation of apolipoprotein B gene is assodiated with myocardial infarction and lipoprotein levels in dans[J].Atherosclerosis,1991,89(2):69.
[98]Guzman EC,Hirata MH,Quintao EC,et al.Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk of coronary heart disease.Clin Chem Lab Med,,2000,38:731-6.
[99]Myant NB,Gallagher J,Barbir M,et al.restriction fragment length polymophisms in the apoB gene in relation to coronary artery disease,atherosclerosis.1989,77:193-201.
[100]Pan JP,Chiang AN,Tai JJ,et al.Restriction fragment length polymorphisms of Apolipoprotein B gene in Chinese population with coronary heart disease.Clin Chem,1995,41:424-9.
[101]Priestly L,Knott T,Wallis S,et al.RFLP for the human apolipoprotein B gene:V;XbaI,Nucleic Acids Res,1985,13:6789.
[102]叶平,王士雯,陈宝生.中国人冠心病与载脂蛋白B基因Xba Ⅰ酶切多态性关联的研究.中华医学遗传学杂志,1995,12:75-78.
[103]Park KW,Choi JH,Kim HK,et al.The association of cholesteryl ester transfer protein polymorphism with high - density lipoprotein cholesterol and coronary artery disease in Koreans[J].Clin Genet,2003,63(1):31 - 38
[104]Brousseau ME,O'Connor JJ,Ordovas JJM,et al.Cholesteryl ester transferprotein TaqIB2B2 genotype is associatedwith higherHDL cholesterol levers and lower risk of coronary heart disease end points in men with HDL deficiency:Veterans Affairs HDL Cholesterol Intervention Trial[J].Arterioscler Thromb VascBiol,2002,22(7):1148 -1154
[105]Genest JJ Jr,Martin-Munley SS,Mc Namara JR,et al.Familial lipoprotein disorders in patients with premature coronary artery disease.Circulation,1992,85:2025-2033.
[106]Bu X,Warden CH,Xia YR,et al.Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition:evidence for involvement of the apolipoprotein A-Ⅱ and cholesteryl ester transfer protein loci.Hum Genet,1993,93:639-648.
[107]Ordovas JM,Cupples LA,Corella D,et al.Association of cholesteryl ester transfer protein-TaqIB polymorphism with variation in lipoprotein subclasses and coronary heart disease risk:the Framingham Study.Arterioscler Thromb Vasc Biol,2002,20:323-329.
[108]Hsu LA,Ko YL,Hsu KH,et al.Genetic variations in the cholesteryl ester transfer protein gene and high density lipoprotein cholesterol levels in Taiwanese Chinese[J].Hum Genet,2002,110(1):57 - 63
[109]Maruyama T,SakaiN,IshigamiM,et al.Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalpha lipoproteinemia [J].Atherosclerosis,2003,166(1):177-185.
[110]Inazu A,Jiang XC,Haraki T,et al.Genetic cholesteryl ester transfer protein deficiency caused by two prevalence mutations as a major determinants of increased levels of high density lipoprotein cholesterol.J Clin Invest,1994,94:1872-1882.
[111]王伟,周新,刘芳,等.胆固醇脂转运蛋白基因TaqIB多态性、D442G突变与冠心病的相关性研究.中华心血管病杂志,2004,11(32),981-985.
[112]Sakai N,Yamashita S,Hirano K,et al.Frequency of exon 15 missens mutation(442D:G)in cholesteryl ester transfer protein gene in hyperalpha lipoproteinemic Japanese subjects.Atherosclerosis,1995,114:139-145.
[113]Bu X,Warden CH,Xia YR,et al.Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition:evidence for involvement of the apolipoprotein A-Ⅱ and cholesteryl ester transfer protein loci.Hum Genet,1993,93:639-648.
[114]Takahashi K,Jiang XC,Sakai N,et al.Amissense mutateon in the cholesteryl ester transfer protein gene with dorninant effects on plasma high density lipoproteins[J].J Clin Invest.1993,92:2063 - 2064.
[115]Boekholdt SM,Thompson JF.Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease[J].J Lipid Res,2003,44(6):1080-1093.
[116]Ordovas JM,Cupples LA,Corella D,et al.Assoyciation of cholesteryl ester transfer protein-TaqIB polymorphism with variation in lipoprotein subclasses and coronary heart disease risk:the Framingham Study.Arterioscler Thromb Vasc Biol,2002,20:323-329.
[117]Inazu A,Jiang XC,Haraki T,et al.Genetic cholesteryl ester transfer protein deficiency caused by two prevalence mutations as a major determinants of increased levels of high density lipoprotein cholesterol.J,Clin Invest,1994,94:1872-1882.
[118]Yamashita S,Hirano K,Sakai N,et al.Molecular biology and pathophysiological aspects of plasma cholesteryl estertransfer protein[J].Biochim Biophys Acta,2000,1529(1-3):257-275.
[119]Ordovas JM.Genetic polymorphisms and activity of cholesterol ester transfer protein(CETP):should we be measuring them?[J].Clin Chem Lab Med,2000,8(10):945-949.
[120]汪俊军,强红娟,等.心脑血管疾病患者胆固醇酯转运蛋白及某些基因缺陷[J].中华检验医学杂志,2001,24(2):98-101.
[121]Akita H,Chiba H,Hui SP,et al.Cholesteryl ester transfer protein deficiency:identification in the Chinese[J].Am J MedGenet,1995,59:399-400.
[122]Kuivenhoven JA,de Knijff P,Boer JM,et al.Heterogeneity at the CETP gene locus.Influence on plasma CETP concentrations and HDL cholesterol levels[J].Arterioscler Thromb Vasc Biol,1997,17(3):560-568.
[123]Ishikawa Y,ItoK,Akasak Y,et al.The distribution and production of cholesteryl ester transfer proteinin the human aortic wall[J].Atherosclerosis,2001,156(1):29-33.
[124]Hui SP.Frequency and effect on plasm lipoprotein R metabolism of a mutation in the cholesterol easter transfer protein gene in the Chinese[J].Hokkaido Igaku Zasshi(北海道医学杂志),1997,73:319.
[125]沈晶晶,杨泽,惠淑萍,等.中国人胆固醇酯转运蛋白(CETP)基因的变异[J]基础医学与临床,1999,19,85.
[126]庄-义,汪俊军,强红娟,等.心脑血管疾病患者胆固醇酯转运蛋白及某些基因缺陷[J].中华检验医学杂志,2001,24(2):98-101.
[127]郑克勤,张思仲,张克兰,等.胆固醇酯转运蛋白基因突变及其与冠状动脉粥样硬化性心脏病易感性的关联研究[J].中华医学遗传学杂志,2003,20(1):23226.
[128]Ordovas JM,Cupples LA,Corella D,et al.Association of cholesterylester transfer protein-TaqIB polymorphism with variation in lipoprotein subclasses and coronary heart disease risk:the Framingham Study.Arterioscler Thromb Vasc Bid,2002,20:323-329.
[129]Expert Panel on detection,evaluation and treatment of high blood cholesterol in adults.Executive surmmary of the third report of the national cholesterol edueation Program(NCEP)expert Panalondetection,evaluation,and treatment of high blood Cholesterol in adults(adult treatment Pnaell 11).JAMA,2001,285:2486-2497.
[130]Akita H,Chiba H,Hui SP,et al.Cholesteryl ester transfer protein deficiency:identification in the Chinese[J].Am J Med Genet,1995,59:399-400.
[131]Yamashita S,Hirano K,Sakai N,et al.Molecular biology and pathophysiological aspects of plasma cholesteryl estertransfer protein[J].Biochim Biophys Acta,2000,1529(1-3):257-275.
[132]Ordovas JM.Genetic polymorphisms and activity of cholesterol ester transfer protein(CETP):should we be measuring them?[J]Clin Chem Lab Med,2000,38(10):945-949.
[133]Nabila AA,Olusegun AM,Abayomi OA,et al.Serum lipoprotein(a)concentration as a cardiovascular risk factor in Kuwaiti type 2diabetic patients[J].J Diabetes Complications,2001,15:270.
[134]Kesavulu MM,Kameswara BR,Giri R,et al.Lipid peroxidation-and antioxidant enzyme status in type 2 diabetics with coronaryheart disease[J].Diabetes Res Clin Pract,2001,53:33.
[135]王薇.赵东.刘静,等.中国3564岁人群心血管病危险因素与发病的前瞻性研究[J].中华心血管病杂志,2003,31:902908.
[136]徐成斌·糖尿病血脂异常与冠心病[J]·中国糖尿病杂志,2002,10:319-320。
[137]American Diabetes Association.Screening for type 2 diabetes[J].DiabetesCare,2000,23(supple 1):20-23
[138]MalgorZataBartnik,LarsRyden Roberto Ferrariet al.The Prevalence of abnormal glucose regulation in Patients with coronary artery diseasea cross.Europe European Heart Journal 2004;25:1880-1890.
[140]wiswanathan V,Snethalatha C,Wair MB et al.Markers of endothelial in hyper glycaemic asia India subjects.J Diabetes Complications.2004:18(1):47-52.
[1]Calandra S,Oliva CP,Tarugi P,Bertolini S.APOA5 and triglyceride metabolism,lesson from human APOA5 deficiency.Curr Opin Lipidol.2006;17:122-127.
[2]Talmud PJ.Rare APOA5 mutations-Clinical consequences,metabolic and functional effects An ENID review.Atherosclerosis.In press.
[3]Pennacchio LA,Olivier M,Hubacek JA,Krauss RM,Rubin EM,Cohen JC.Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.Hum Mol Genet.2002;11:3031-3038.
[4]Talmud PJ,Hawe E,Martin S,Olivier M,Miller GJ,Rubin EM,Pennacchio LA,Humphries SE.Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.Hum Mol Genet.2002;11:3039-3046.
[5]Merkel M,Loeffler B,Kluger M,Fabig N,Geppert G,Pennacchio LA,Laatsch A,Heeren J.Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteogly can-bound lipoprotein lipase.J Biol Chem.2005;280:21553-21560.
[6]Alborn WE,Prince MJ,Konrad RJ.Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes.Clin Chim Acta.2007;378:154-158.
[7]Dallinga-Thie GM,van Tol A,Hattori H,van Vark-van der Zee LC,Jansen H,Sijbrands EJ.Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.Drabetologia.2006;49:1505-1511.
[8]Henneman P,Schaap FG,Havekes LM,Rensen PC,Frants RR,van Tol A,Hattori H,Smelt AH,van Dijk KW.Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism.Atherosclerosis.In press.
[9]Pennacchio,L.A.Olivier.M,Hubacek,J.A,et al.An Apopipoprotein In fluencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing.Science.2001,27:234-236.
[10]Vander Vliet HN,Shcapa FG,vels JH,et al.Adenoviral over expression of apolipoprotein-Averduees seurm levels of triglycerides and cholesterolimic[J].Biochem Bio ResCommun,2002,295(5):1156-1159.
[11]Burns GA,Karathnaasis SK,Breslow JL.Human apaolipoprotein.A-I-C-111 gene complex is located on chromosome,arteriosclerosis.1984,4(2):97-102.
[12]Alborn WE,Jo hnson M G,Prince MJ,et al.Definitive terminal protein sequence and further characterization of the novel apolipop rotein A5 inhuman serum[J].Clin Chem,2006,52:514-517.
[13]0'Brien PJ,Albom WE,Sloan J H,et al.The novel apolipoprotein A5 is p resent in human serum,is associated with VLDL,HDL,and chylo microns,and circulates at very low concent rations compared with her apolipoproteins[J].Clin Chem,2005,51:351-359.
[14]Lee SJ,Moye LA,Campos H,et al.Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CⅢ in patients with coronary heart disease.Atherosclerosis.2003 Apr;167(2):293-302.
[15]Wei Huang,Nan Bi,Xiao hong Zhang,et al.Overexpression of apolipop rotein A Vin the liver reduces plasma t riglyceride and cholesterol but not HDL in Apo E deficient mice[J].Biochemical and Biophysical Research Communications,2006,46:14218.
[16]Baroukh N,Bauge E,Akiyama J,et al.Analysis of Apolipoprotein A5,C3,and Plasma Triglyceride Concent rations in Genetically Engineered Mice[J].Arterioscler T hromb Vasc Biol,2004,24:1297-1302.
[17]Najib J F,Bauge E,Niculescu L S,et al.Mechanism of triglyceride lowering in mice exp ressing human apolipoprotein A5[J].Biochemical an d B iop hysical Research Com m unications,2004,319:397-404.
[18]Henneman P,Schaap F G,Havekes L M,et al.Plasma ApoA5 levels are markedly elevated in severe hypert riglyceridemia and positively correlated with the ApoA5 S19W polymorphism[J].At hero sclerosis,2007,193(1):129-134.
[19]Kort EN,Ballinger DG,Ding W,et al.Evidence of linkage of familial hypoalpha lipoproteinemia to a novel locus on chromosome 11q23.Am J Hum Genet.2000 Jun;66(6):1845-56.Epub 2000 Apr 17-32
[20]Lusis AJ.Atherosclerosis.Nature.2000,407:233-241.
[21]Ishihara M,Kujiraoka T,Iwasaki T,Nagano M,Takano M,Ishii J,et al.A sandwich enzyme linked immunosorbent assay for human plasma apolipoprotein AV concentration[J].J Lipid Res,2005,46(9):2015-022.
[22]Itamar Grosskopf,Nadine Baroukh,Sung-Joon Lee,et al.Apolipoportein A-deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of theire remnants[J].Atherosclerosis Thromb Vasc Biol.2005 Dec:25(12):2573-9.
[23]Marcais C,Verges B,Charriere S,et al.Apoa5Q139X truncation Predisposes to Late-onset hyperchylomicronemia due to lipoportein lipase impairment[J].J Clin Invest.2005 oct;115(10):2862-9.
[24]Lookene A,Bekcstead JA,Nilsson S,et al.Apolipoprotein A-V-heparin interactions:impliactions for plasma lipoprotein metabolism[J].J Biol Chem.2005280(27):25383-25387.
[25]Horinek A,Vrablik M,Ceska R,et al.T-1131T>C polymorphism within the apolipoprotein AV gene hypertriglyceridemic individuals.Athero sclero sis,2003,167:369-370.
[26]Grosskopf I,Baroukh N,Lee SJ,et al.Apolipop rotein AV deficiency result s in marked hyper triglyceridemia at tributable to decreased lipolysis of t riglyceride rich lipoproteins and removal of their remnants[J].Arterioscler Thromb VascBiol,2005,25(12):2573-2579.
[27]Talmud.PJ,Cooper J A,Hattori H,et al.The apolipoprotein A V genotype and plasma apolipop rotein A V and t riglyceride levels:p rospective risk of t ype 2diabetes.Result from the Northwick Park Heart Study Ⅱ[J].Di abetologia,2006,49:2337-2340.
[28]Hubacek JA,Skodova Z,Adamkova V,et al.The influence of APOAV Polymorphisms (-1131 T>C and 519>W)on Plasma triglyceride levels and risk of Myocardial infarction.ClinGenet,2004,65(2):126-130.
[29]刘合琨,王春婷,张思仲,等.APOA5基因单核苷酸多态性与冠心病相关性研究.中华医学遗传学杂志.2004,21:335-338.
[30]Liu H,Zhang S,Lin J,LIH,etal.Association betwene DNA variant sites in the Apolipoprotein AS gene and coronary heart disease in Chinese[J].Metabolism.2005May;54(5):568-572.
[31]Endo K,Yamgi H,Arak J et al Association found between the promoter region polymorphism in the apolipoprotein AV gene and the serum triglycerid level in Japanese School children.Hum Genet,2002,111:570-572.
[32]Nabika J,Nasreen S,Kobayashi S,et al.The genetic effect of the apoliprotein AV gene on the serum triglycerid level in Japanese.Atherosclerosis,2002,165:201-204
[33]Lai CQ,Demissie S,Cupples LA,et al.Influence of the APOA5 locus on Plasma triglyceride,lipoprotein subclasses,and CVD risk in the Framingham Heart Sutdy[J].J Lipid Res.2004 Nov;45(11):2096-105.
[34]Jang,Kim JY,et al.The-1131-T>C Polymorphism in the Apolipoportein A5 gene Is associated with Postprandial hyper triglyceridenemia:elevated small,denseLDL concentrations;and oxidative stress in nonobese Korean men[J].Am J Clin Nutr.2004Oct;80(4):832-40.
[35]Li GP.The new member of the apolipoprotein gene family:the study of apolipoprotein A5 gene.Chin J Arterioscler,2004,12:229-232.
[36]Baum L,Tomlinson B,Thomas GN.APOA5-1131T>C Polymorphism is associated with triglyceride levels in Chinese men[J].ClinGenet.2003 May;63(5):377-9.
[37]Kao J,Wen H,Chien K,et al.A novel genetic variant in the apoli-poprotein A5 gene is associated with hypertriglyceridemia[J].Hum Mol Genet,2003,12(19):2533-2539.
[38]Tahnud P J,Martin S,Taskinen MR,et al.APOA5 gene variants,lipoprotein particle distribution,and progression of coronary heart disease:results from the LOCAT study[J].J Lipid Res.2004,45:750-756.
[39]Hubek JA,Admkov V,Eka R,et al.New variants in the apolipoproteinAV gene in individuals with extreme tri glyceride levels[J].PhysiolRes,2004,53(2):225 -228.
[40]Sun GT,Bi N,Li GP,Zhu XW,Zeng WW,Wu G,et al.Identification oflipid binding and lipoprotein lipase activation domains of human apoAV[J].JChem Phys Lip,2006,143(122):22-28.
[41]Hsu,LA,Chang,CF.Hu,S.Wu,et al.2006.Genetic variations of apolipoprotein A5gene is associated with the risk of coronary artery disease among Chinese in Taiwan.Atherosclerosis.185:143-149.
[42]毕楠,郡盛恺,李国平等。冠心病患者载脂蛋白A5和载脂蛋白C3基因多态性的研究[J],中华心血管病杂志,2005(33)2:116-121。
[43]Martin S,Nicaud V,Humphries SE,et al.Conrtibution of APOA5 gene variants To Plasma triglyeceride determination and to the response to both fat and glucose Tolerance challenges[J].Biochim-Biophys-Acta.2003Apr 17;1637(3):217-25.
[44]Lai CQ,Tai ES,Tan CE,et al.The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore[J].J Lipid Res,2003,44(12):2365-2373.
[45]Austin MA,Talmud PJ,Farin FM,et al.Association of apolipoprotein A5variants With LDL Particle size and triglyceride in Japanese Americans[J].Biochim -Biophys -Acta.2004 Jan 20;1688(1):1-9.
[46]SzalaiC,Keszei M,Duba J,et al.Polymorphism in the promoter region of the Apolipoprotein A5 gene is associated with an increased susceptibility for coronary Artery disease[J].Atherosclerosis.2004Mar;173(1):109-14.
[47]Lai,C.Q.,S.Demissie,L.A.Cupples,Y.et al...Influence of the APOA5 locus on plasma triglyceride,lipoprotein subclasses,and CVD risk in the Framingham Heart Study.J.Lipid Res.2004 45:2096-2105.
[48]Lee KW,Ayyobi A,Frohlich JJ,et al.APOA5 gene Polymorphism modulates Levels of triglyceride,HDL cholesterol and FERHDL but is not a risk factor for Coronary artery disease[J].Atherosclorosis.2004 SeP:176(1):165-72.
[49]Ruiz-Navraez EA,YangY,Nakanishi Y,et al.APOC3/A5hpalotypes,lipid levels,And risk of myocardial in farction in the Central Valley of Costa Rica[J].J Lipid Res.2005 Dec;46(12):2605-13.
[50]Su LA,KoYL,Chang CJ,et al.Genetic valuations of apaolipoprotein A5 gene is Associated with the risk of coronary artery disease among Chinese inTaiwan[J].Atherosclerosis.2005 Jul 26;
[1]Kim,HK;Chang,SA;Choi,EK;Kim,YJ;Kim,HS;Solm,DW;Oh,BH;Lee,MM;Park,YB;Choi,YS.Association between plasma lipids,and apolipoproteins and coronary artery disease:a cross-sectional study in a low-risk Korean population.Int J Cardiol.2005;101:435-440.
[2]Marz,W;Scharnagl,H;Winkler,K;Tiran,A;Nauck,M;Boehm,BO;Wikelmann,BR.Low-density lipoprotein triglycerides associated with low-grade systemic inflammation,adhesion molecules,and angiographic coronary artery disease:the Ludwigshafen Risk and Cardiovascular Health study.Circulation.2004;110:3068-3074.
[3]Achari,V;Thakur,AK.Association of major modifiable risk factors among patients with coronary artery disease-a retrospective analysis.J Assoc Physicians India.2004;52:103-108.
[4]Walldius,G;Jungner,I;Holme,I;Aastveit,AH;Kolar,W;Steiner,1~.High apolipoprotein B,low apolipoprotein A-I,and improvement in the prediction of fatal myocardial infarction(AMORIS study):a prospective study.Lancet.2001;358:2026-2033.
[5]Rosenson,R.Lipoprotein classification;metabolism;and role in atherosclerosis.In:Rose B.,editor.UpToDate.Wellesley,MA,USA:UpToDate;2005.
[6]陶寿淇.血脂与冠心病[J].中华心血管病杂志,1997,25(3):234.
[7]HollanderW.Unified concept on the role of acid mucopolysaccharides and connective tissue proteins in the accumulation of lipids,lipoproteins,and calcium in the atherosclerotic plaque.Exp Mol Pathol.1996,25(1):106-120.
[8]Chiodini BD,Barlera S,Franzosi MG,et al.APOB gene polymorphislns and coronary artery disease:a meta analysis Atherosclerosis,2003:355-366.
[9]Genest JJ Jr,Ordovas JM,McNamara JR,et al.DNApolymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease.Atheros-Clerosis,1990,82:7-17.
[10]叶平,王士雯,陈宝生.中国人冠心病与载脂蛋白B基因Xba Ⅰ酶切多态性关联的研究.中华医学遗传学杂志,1995,12:75-78.
[11]Sniderman AD,St-Pierre AC,Cantin B,Dagenais GR,Despres JR Lamarche B.Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atheroscterotic risk.Am J Cardiol.2003;91:1173-1177.
[12]Keulen ET,Kruijshoop M,Schaper NC,Hoeks AP,de Bruin TW.Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B.Arterioscler Thromb Vasc Biol.2002;22:283-288.
[13]Campos H,Khoo C,Sacks FM.Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL,IDL,and LDL from normolipidemic humans.Atherosclerosis.2005;181:345-351.
[14]Sharrett AR,Ballantyne CM,Coady SA,Heiss G,Sorlie PD,Catellier D,Patsch W.Coronary heart disease prediction from lipoprotein cholesterol levels,triglycerides,lipoprotein(a),apolipoproteins A-I and B,and HDL density subfractions:the Atherosclerosis Risk in Communities(ARIC)Study.Circulation.2001;104:1108-1113.
[15]Saha M,Tay JS,Jeyaseelan K,et al.DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients.Clin Genet,1992,42:164
[16]Demant T,Houlston RS,CaslakeMJ,et al.Catabolic rate of low density lipoprotein is influenced by variation apohpoprotien B gene.J,Clin Invest,1998,82(3),797-802.
[17]Series J,Cameron J,Caslake M,et al.The Xbal polymorphism of the apohpoprotien B gene influences the degradation of low density lipoprotein in vitro.Biochim Biophys Acta,1999,1003(2):183-188.
[18]Renges HH,Wile DB,Mckeigue PM,et al.A lipoprotein B polymorphisms are associated with lipid leves in man of south Asian desents.Atherosclerosis,1991,91:267.
[19]Turner PR,Talmud PJ,Visvikis S,et al.DNA polyphism of the apolipoprotein B gene are associated with altered Plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease:European.atherosclerosis reserch study.Athersclerosis,1995,116:221.
[20]Tyjerg HA,Nordestgard BG,Gerdes LU,et al.variation of apolipoprotein B gene is associated with mycardiol infaction and lipoprotein leves in Danes.Atherosclerosis,1991,89:69.
[21]Ye P,Chen B,Wang S.Assocition of polymorphism of the apolipoprotein B gene with coronary heart disease in Han Chinese.Atherosclerosis.1995,117(1),43-50.
[22]Wick U,Witt E,Engle E.Restriction fragment length polymorphism at the apolipoprotein genes A1,C3,and B100 and in the 5'flanking region of insulin gene as possible markers of coronary heart disease.Clin Genet,1995,47:184-190.
[23]Tybiaerg-Hansen A,wordestgaard BG,et al.Variation of apolipoprotein B gene is assodiated with myocardial infarction and lipoprotein levels in dans[J].Atheros- clerosis,1991,89(2):69.
[24]叶平,王士雯,陈保生.载脂蛋白B基因多态性与冠心病关系的研究[J].中华心血管病杂志,1994,22(2):119.
[25]Priestly L,Knott T,Wallis S,et al.RFLP for the human apolipoprotein B gene:V;XbaI,Nucleic Acids Res,1985,13:67-89.
[26]张岸平,姜玉如,武守山.载脂蛋白B基因Xbal和EcoRl酶切位点多态性与冠心病和血脂水平的关联研究[J].中华医学遗传杂志,2002,19(5):435-437.
[27]Myant NB,Gallagher J,Barbir M,et al.Restriction fragment length polymorphism in the apoB gene in relation to coronary disease.Arteriosclerosis,1989,77:193-201.
[28]Paulweber B,Friedl W,Krempler F,et al.Association of DNA polylnorphism at the apolipoprotein B gene locus with coronary heart disease and serum very low density lipoprotein levels.Arteriosclerosis,1990,10:17-24.
[29]Nabika T,Nasreen S,Kobayashi S,et al.The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese.Atherosclerosis 2002:201-204
[30]Humpbaries SE.DNA Polymorphisms of the Apolipoprotein Genes-their Use in the Investigation of the Genetic Component of Hyperlipidemia and Athcrosclerosis[J].Atherosclerosis,1988,72:89-108.
[31]ChoiKM,LeeKW,Kim SQ et al.Inflammation,insulin resistance and glucose in tolerance in acute myocardial infarction Patients without a Previous diagnosis of diabetesmellitus,J Clin Endocrino 1 Metab,2005,90:175-180.
[32]Gallagher J J,Myant NB.Does the EcoR I Polymorphism in human apolipoproteinB gene affect the binding of low density lipoprotein to low density lipoprotein receptor[J].Arterioscler thromb,1992,12(2):256-260.
[33]鄢盛恺,李秀玲,薛红等汉族人载脂蛋白B基因EcoR Ⅰ Msp Ⅰ多态性与冠心病的关系研究.中华医学检验杂志,2003,26:148-152.
[34]叶平,陈保生,王士雯.应用聚合酶链反应研究载脂蛋白B基因多态性及其临床意义.中华医学检验杂志,1994,17:7-11.
[35]Whitfield,A;Barrett,P;van Bockxmeer,F;Burnett,J.Lipid disorders and mutations in the APOB gene.Clin Chem.2004;50:1725-1732.
[36]李飞雪,黄体钢,李正言.载脂蛋白B基因多态性与血脂代谢及冠心病关系的研究[J].中华心血管病杂志,1998,26(3):180.
[37]Boerwinkle E,Lee SS,Butler R,et al.Rapid typing of apolipoprotein B DNA polymorphisms by DNA amplification:association between Agepitopes of human apolipoprotein B-100,a signal peptide insertion/deletion polymorphism,and a 3' flanking DNA variable number of tandem repeats polymorphism of the apolipoprotein B gene.Atherosclerosis,1990,81:225-232.
[38]徐琼,周新.载脂蛋白B基因MspI多态性分析及其临床应用.临床检验杂志,1998,16:199-201.
[39]Jiang R,Schulze MB,Li T,Rifai N,Stampfer M J,Rimm EB,Hu FB.Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.Diabetes Care.2004;27:1991-1997.
[40]RajPut-Williamas S,Knott JTJ,Wallis SC,et al.Varoation of apoB gene is Assoeiated with obesity,high blood cholesterol levels,and inceased risk of coronary heart diseases.Lancet,1988:2:1441
[41]Delghandi M,Thangarajah R,Nilsen M,et al.DNA polymorphisms of he apolipoprotein B gene(XbaI,EcoRI,and MspI RFLPs)in orwegians at risk of atherosclerosis and healthy controls.Acta Cardiol,1999,54:215-225.
[42]Rackley,C.Pathogenesis of atherosclerosis.In:Rose B.,editor.UpToDate.Wellesley,MA,USA:UpToDate;2005.
[43]Stepnaov VA,Puzyrev VP,Lemza SV;et al.Interrelationship between structure variants of the apolipoprotein B and ischemic heart disease and plasma lipid levels.Genetica,1995,31(3):405-409.
[44]Machado MO,Hirata MH,Bertolami MC,et al.Apo B gene haplotyis associated with lipid profile of higher risk for coronary heart disease Caucasian Brazilian men.J Clin Lab Anal.200 I,15:19-24.
[45]Heng CK,Saha N,LowPS.Evolution of the apolipoprotein B gene a coronary artery disease:a study in low and high risk Asians.Ann Hu Genet,1999,63:45-62.
[46]Xu CF,Nanjee MN,Savill,et al.Variation at the apohlipoprotein(ao)Al-C3-SIV Gene cluster and apoB gene levels in Italian children.AmJ Humgene,1990,47;429.
[47]Choong ML,Koay ES,Khaw MC,et al.Apolipoprotein B 5'-Ins/Del and 3'-VNTR Polymorphism in Chinese,Maiayand Indian Singaporeaans[J]Hum Hered,1999,49(1):31-40
[48]Wu JH,Wen MS,Lo SK,et al.DNA Polylmorphisms of apolipoproteinB in The population of Taiwan J Formos Med Assoc.1993APr;92(4)330-5.
[49]Peacock R,Draining A.Hamsten A,et al.Apolipoprotein B gene Polymorphisms,Lipoproteins and coronary atherosclerosis:a study of young myocardial infarction survivors and healthy population-based individuals.Atherosclerosis.1992,Feb;92(2-3):151-64..
[50]Jaramillo-Correa,JP;Keyeux,G;Ruiz-Garcia,M;Rodas,C;Bernal,J.Population genetic analysis of the genes APOE,APOB(3'VNTR)and ACE in some black and Amerindian communities from Colombia.Hum Hered.2001;52:14-33.
[51]Verbenko,DA;Pogoda,TV;Spitsyn,VA;Mikulich,AI;Bets,LV;Bebyakova,NA;Ivanov,VP;Abolmasov,NN;Pocheshkhova,EA;Balanovskaya,EV;Tarskaya,LA;Sorensen,MV;Limborska,SA.Apolipoprotein B 3'-VNTR polymorphism in Eastern European populations.Eur J Hum Genet.2003;11:444-451.
[52]Horvath,A;Chorbov,V;Zaharova,B;Ganev,V.Five polymorphisms of the apolipoprotein B gene in healthy Bulgarians.Hum Biol.2003;75:69-80.
[53]Verbenko,DA;Knjazev,AN;Mikulich,AI;Khusnutdinova,EK;Bebyakova,NA;Limborska,SA.Variability of the 3'APOB minisatellite locus in Eastern Slavonic populations.Hum Hered.2005;60:10-18.
[54]Friedl W,Ludwif EH,Paulweber B,et al.HyPervariability in a mini satellites as templates and the mechanism of their replication.Proc Natl Acad Sci USA,1994,51:315-323
[55]Yan,SK;Song,YH;Zhu,WL;Yan,XW;Xue,H;Du,H;Chen,BS.Apolipoprotein B gene 3'VNTR polymorphism:association with plasma lipids and coronary heart disease in Han Chinese.Clin Chem Lab Med.2006;44:1199-1205.
[56]Friedl W,Ludwig EH,Paulweber B,et al.Hypervariability in a minisatellite 37πof the apolipoprotein B gene in patients with coronary heart disease compared with normal controls.J Lipid Res.l990;31(4):659265
[57]Mohammad Mostafa Zaman,Shinji Ilemoto,Nobuo Yoshiike et al.Association of apolipoprotein gentic Polymorphisms with plasma cholesterol in a Japanese rural population.Arterosclerosis,Thrombosis,and Vascular Biology,1997,17(12),3495-3504.
[58]Ye Ping,ChenBaoSheng,WangShiWen,et al.The assocaiation of polymorphism at a VNTR locus 37πto the apolipoprotein B gene with coronary heart disease in Chinese population.Chin Med Sci J,1995,10(2):63-69.
[59]Pan JP,Chiang AN,Tai JJ,et al.Restriction fragment length polymorphisms of apolipoprotein B gene in Chinese population with coronary heart disease.Clin Chem,1995,41:424-429.
[1]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomized placebo -controlled trial[J].Lancet,2002,360(9326):7222.
[2]Drayna D,Jarnagin AS,McLean J,et al.Cloning and sequencing of human cholesteryl ester transfer protein cDNA.Nature,1987,327:632-634.
[3]黄竹颖.胆固醇酯转运蛋白基因缺陷与动脉粥样硬化关系研究进展.卫生研究,2005,34(6):7652767.
[4]Hirano K,Yamashita S,Matsuzawa Y.Pros and cons of inhibitincholesteryl ester transfer protein[J].Curr Opin Lipidol,2000,1(6):589-596.
[5]焉盛恺.冠心病的危险因素及其临床应用价值.中华检验医学杂志,2001,24:383-385.
[6]王勃,白小涓.载脂蛋白B基因多态性与冠心病的关系[J].中国误诊学杂志,2002,2(6):8522853.
[7]张少敏,胡应龙,方卫华.载脂蛋白B等位基因变异与早发冠心病的关系[J].中国心血管杂志,2003,8(2):21.
[8]Genest JJ Jr,Martin-Munley SS,McNamara JR,et al.Familial lipoprotein disorders in patients with premature coronary artery disease.Circulation,992,85:2025-2033.
[9]Bu X,Warden CH,Xia YR,et al.Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition:evidence for involvement of the apolipoprotein A-Ⅱ and cholesteryl ester transfer protein loci.Hum Genet,1993,93:639-648.
[10]Ordovas JM,Cupples LA,Corella D,et al.Association of cholesteryl ester transfer protein- ymorphism with variation in lipoprotein subclasses and coronary heart disease risk:the Framingham Study.Arterioscler Thromb Vasc Biol,2002,20:323-329.
[11]Inazu A,Jiang XC,Haraki T,et al.Genetic cholesteryl ester transfer protein deficiency caused by two prevalence mutations as a major determinants of increased levels of high density lipoprotein cholesterol.J.Ctin Invest,1994,94:1872-1882.
[12]Thompson JF,Durham LK,LiraM E,etal.CETP polymorphisms associated withHDL cholesterolmay differ from those associated with cardiovascular disease[J].Atherosclerosis,2005,181(1):45-53.
[13]IkewakiK,MabuchiH,Teramoto T,et al.Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects[J].Metabolism,2003,52(12):1564-1570.
[14]Ordovas JM,CupplesLA,Corella D,et al.Association of cholesteryl ester transfer protein TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk:the framingham study.Arteriosclerosis Thromb Vasc Biol,2000,20:1323-1329.
[15]Kuivenhoven JA,de Knijff P,Boer JM,et al.Heterogeneity at the CETP gene locus.influence on plasma CETP concentrations and HDL cholesterol levels[J].Arterioscler Thromb Vasc Biol,1997,17(3):560-568.
[16]刘宽芝,王晓英,张进贵.胆固醇酯转运蛋白及其基因多念性与2型糖尿病大血管病变的关系[J].中国动脉硬化杂志,2003,11(6):549-552.
[17]DeVriesR,Perton F G,Dallinga-Thie G M,et al.Plasma cholesterylester transfer is a determinantof intima-media thickness in type 2 diabetic and nondiabetic subjects:role ofCETP and triglycerides[J].Diabetes,2005,54(12):3554-3559.
[18]Ordovas JM,Cupples LA,Corella D,Otvos JD,Osgood D,Martinez A,et al.Association of cholesteryl ester transfer protein2TaqIB polymorphismwith variations in lipoprotein subclasses and coronary heart disease risk:the Framingham study[J].Arterioscler Thromb Vasc Biol,2000,20(5):1 323-329.
[19]Park KW,Choi J H,Kim HK,Oh S,Chae IH,Kim HS,et al.The association of cholesteryl ester transfer protein polymorphism with high2density lipoprotein cholesterol and coronary artery disease in Koreans[J].Clin Genet,2003,63(1):31-38
[20]Goto A,Sasai K,Suzuki S,Fukutomi T,Ito S,Matsushita T,et al.Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects:a study based on coronary angiography[J].Atherosclerosis,2001,159(1):153-163.
[21]Hodoglugil U,Williamso n DW,Huang Y,et al.An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high density lipoprotein cholesterol levels in Turks.Clin Genet,2005,68(2):118-127.
[22]Arca M,Montali A,Ombres D,Battiloro E,Campagna F,Ricci G,et al.Lack of association of the cornmon TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis[J].Clin Genet,2001,60(5):374-380.
[23]Boekholdt SM,SacksFM,Jukema JW,etal.Cholesteryl ester transfer protein TaqIB variant,high-density lipoprotein cholesterol levels,cardiovascular risk,and efficacy of pravastatin treatment:individual patientmeta-analysis of 13,677 subjects[J].Circulation,2005,111(3):278-287.
[24]Eiriksdottir G,Bolla M K,Thorsson B,Sigurdsson G,Humphries SE,Gudnason V.The 2629C>A polymorphism in the CETP gene does not explain the association of TaqlB polymorphism with risk and age of myocardial infarction in Icelandic men.A therosclerosis,2001,159(1):187-192.
[25]SmaouiM,Hammami S,AttiaN,at el.Modulation ofplasma cholesteryl ester transfer protein activity by unsaturated fatty acids in Tunisian type 2 diabetic women[J].Nutr Metab CardiovascDis,2006,16(1):44-53.
[27]郑克勤,张思仲,张克兰,等.胆固醇脂转运蛋白基因突变及其与冠状动脉粥样硬化性心脏病易感性的关联研究[J]中华遗传学杂志,2003,20(1):23-26.
[28]Zhuang YY,Wang JJ,Qiang HJ.CETP levels and gene deficiency in Chinese Patientswith cardio-cerebrovascular disease[J].Chin,Med J,2002,115(3):371-374.
[29]Funk H,Wiebusch H,Fuer L.Identification of mutations in the cholesteryl easter transerfer protein in Europein with elevated high density lipoprotein cholestrol[J].Circulation 1994,90(sup):S241-S247.
[30]Brousseau ME,O'Connor JJ Jr,Ordovas JM,Collins D,Otvos JD,Massov T,et al.Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency:Veterans Affairs HDL Cholesterol Intervention Trial[J].Arterioscler Throlnb Vasc Biol,2002,22(7):1 148-154.
[31]Zheng KQ,Zhang SZ,He Y,Zhang L,Zhang KL,Huang D J,et al.Association between cholesteryl ester transfer protein gene polymorphisms and variations in lipid levels in patients with coronary heart disease.Chin Med J(Engl),2004,117(9):1288-292.
[32]Blankenberg S,Tiret L,Bickel C,et al.Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease.The Athero Genecase control st udy.Z Kardiol,2004,93(Suppl 4):16-23.
[33]Frisdal E,Klerkx A H,Le Goff W,et al.Functional interaction between 2629C/A,2971 G/A and 21337C/T polymorp hisms in the CETP gene is a major determinant of promoter activity and plasma CETP concent ration in the REGRESS St udy.Hum Mol Genet,2005,14(18):2 607-2618.
[34]黄光英,陆付耳,李鸣真,等.胆固醇酯转运蛋白变异体Ile405Val在欧亚人群中的频率及其对血脂代谢影响的比较研究.中国现代医学研究,1999,9(1):9212.
[35]Bernard S,Moulin P,Lagrost L,et al.Association between plasma HDL cholesterol concentration and TaqIB CETP gene polymorphism in non insulin dependent diabetes mellitus.J Lipid Res,1998,39:59-65.
[36]Funk H,Wiebusch H,Fuer L.Identification of mutations in the cholesteryl ester transfer Protein in Europeans with elevated high density liporotein cholesterol[J].Circulation,1994,90(Suppl):S241-S247.
[37]Kakko S,Tamminen M,Kesaniemi YA.R451Q mutation in the CETP gene is associated with elevated high plasma CETP activity[J].Atherosclerosis,1998,136(2):233-240.
[38]Liu J,Zhao D,Wu GX,et al.Study on the distribution and association of cholesteryl ester transfer protein-TaqIB gene polymorphism and plasma concentration in general Population.Chin J Epidemiol,2003,24:303-304.
[39]Fumeron F,Betoulle D,Luc G,et al.Alcohol intake modulatesthe effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk ofmyocardial infarction.J Clin Invest,1995,96:1664-1671.